CAMBRIDGE, Mass. (BUSINESS WIRE) Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the publication of a manuscript in Cancer Research, a journal of the American Association for Cancer Research (AACR), describ.
- Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck- Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring Principal Investigator Glenn J. Hanna, M.D.CAMBRIDGE, Mass. (BUSINESS WIRE) Bicara Therapeutics, a clinical-s.